TEVERELIX ACETATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C74H100ClN15O14.C2H4O2
Molecular Weight	1519.183
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)=O.CC(C)C[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CC=CN=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC=C5C=CC=CC5=C4)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O

InChI

InChIKey=RHXRCUIAKDCELH-DBHPVPIESA-N

InChI=1S/C74H100ClN15O14.C2H4O2/c1-43(2)35-57(66(96)84-56(19-10-11-32-79-44(3)4)73(103)90-34-14-20-63(90)72(102)81-45(5)64(76)94)85-65(95)55(18-9-12-33-80-74(77)104)83-68(98)59(38-48-24-29-54(93)30-25-48)88-71(101)62(42-91)89-70(100)61(40-50-15-13-31-78-41-50)87-69(99)60(37-47-22-27-53(75)28-23-47)86-67(97)58(82-46(6)92)39-49-21-26-51-16-7-8-17-52(51)36-49;1-2(3)4/h7-8,13,15-17,21-31,36,41,43-45,55-63,79,91,93H,9-12,14,18-20,32-35,37-40,42H2,1-6H3,(H2,76,94)(H,81,102)(H,82,92)(H,83,98)(H,84,96)(H,85,95)(H,86,97)(H,87,99)(H,88,101)(H,89,100)(H3,77,80,104);1H3,(H,3,4)/t45-,55-,56+,57+,58-,59+,60-,61-,62+,63+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C74H100ClN15O14
Molecular Weight	1459.131
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C2H4O2
Molecular Weight	60.052
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10872648 | https://www.ncbi.nlm.nih.gov/pubmed/20514551 | https://www.ncbi.nlm.nih.gov/pubmed/12878396

Teverelix is a polypeptide gonadotropin-releasing hormone (GnRH) antagonist which was being developed by Ardana Bioscience for the treatment of prostate cancer and benign prostatic hyperplasia. Compared with other GnRH antagonists, Teverelix is characterized by relatively good water solubility, little in vitro aggregation, and low histamine-releasing potency, with a dose that produces the halfmaximal response. In preclinical studies, Teverelix has been shown to exert antiovulatory activity. In phase I clinical trials Teverelix shows pronounced luteinizing hormone and testosterone suppressive effects after single subcutaneous doses in healthy men.

Approval Year

PubMed

Title	Date	PubMed
Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.	2000-06	10872648
Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay.	1997-08-15	9300077

Patents

Sample Use Guides

In Vivo Use Guide

0.5, 1, 2, 3, or 5 mg

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Wed Apr 02 20:52:39 GMT 2025` Edited by `admin` on `Wed Apr 02 20:52:39 GMT 2025`
Record UNII	RGS9XB9YPC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEVERELIX ACETATE

Common Name

English

D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-L-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-, acetate (1:?)

Preferred Name

English

Code System Code Type Description

FDA UNII

RGS9XB9YPC

Created by admin on Wed Apr 02 20:52:39 GMT 2025 , Edited by admin on Wed Apr 02 20:52:39 GMT 2025

PRIMARY

CAS

500717-25-9

Created by admin on Wed Apr 02 20:52:39 GMT 2025 , Edited by admin on Wed Apr 02 20:52:39 GMT 2025

NON-SPECIFIC STOICHIOMETRY

Related Record Type Details


					D19V7048JK

TEVERELIX

PARENT -> SALT/SOLVATE

Amount: